gracecastuc-066_lung_dr. lecia sequist on relevant emerging molecular targets in lung cancer
Published 11 years ago • 47 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
5:42
gracecastuc-006 - which patients with advanced lung cancer should potentially receive local therapy?
-
5:24
gracecastuc-023_lung_dr. lecia sequist on molecular marker testing in advanced nsclc in 2013
-
17:54
gracecast-066_lung-cancer_expert round table - nsclc molecular markers case 2
-
1:04
gracecastuc-040_lung_can we bring the advances in targeted therapy to broader nsclc populations?
-
3:32
gracecastuc084_lung_dr. sequist on manage acquired resistance
-
17:36
gracecast-096_lung-cancer_mm in lc pt 1: dr. charles rudin on the lung cancer mutation consortium
-
1:36
gracecastuc-074_lung_will gains in targeted therapies be generalizable to other cancers?
-
2:58
gracecastuc-068_lung_dr. oxnard on what molecular markers to test for in advanced nsclc
-
2:59
gracecastuc 125 lung_gains in targeted therapies generalizable to wider range of lung cancers
-
2:21
gracecastuc-060_lung_dr. riely on promising new targeted agents and molecular pathways for lc
-
5:11
gracecastuc-015_lung_what is the biology of a mixed response in lung cancer?
-
4:30
gracecast-117_lung-cancer_asco 2012 lc highlights: dr. neal on molecular targets in squamous nsclc
-
1:23
gracecastuc-067_lung_dr. goldberg on utility of molecular marker results in the adjuvant setting
-
2:07
gracecastuc-046_lung_which new targets and therapies could we bring to lc clinic in near future?
-
6:11
gracecastuc-012_lung_the more you seek, the more you find
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?
-
11:34
squamous lung cancer, part 2: genomic testing
-
2:26
gracecastuc-061_lung_dr. sandler: my approach to acquired resistance for targeted therapies in lc
-
8:06
gracecast-145_lung_highlights in lung cancer, 2013: squamous cell nsclc and antipd1